As TP53 mutation is the most frequently detected mutation in bladder cancer patients (Lamy et al., 2006), we intend to study whether clustering analysis of data from molecular profiling would define TP53 mutant bladder tumors as a subgroup to help identify some novel individualized treatment methods. Here, TP53 is linked to urinary bladder neoplasm.